| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Chrysoeriol has been shown to potently inhibit the induction of nitric oxide synthase by blocking activator protein 1 (AP-1) activation, contributing to its anti-inflammatory effects. It can inhibit PDGF-Rbeta phosphorylation, including ERK1/2, p38, and Akt phosphorylation. It is active against Gram-positive bacteria such as E. faecalis and B. subtilis. Chrysoeriol targets various signaling pathways involved in inflammation, cancer, and microbial infection.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that chrysoeriol has antioxidant, anti-inflammatory, antitumor, antimicrobial, antiviral, and free radical scavenging activities. It potently inhibits the induction of nitric oxide synthase by blocking AP-1 activation. It also shows a selective bronchodilator effect. The compound is active against Gram-positive bacteria. In vitro assays typically involve treatment of cultured cells with chrysoeriol and measuring its effects on various cellular processes.
|
| ln Vivo |
In vivo activity data for chrysoeriol have been reported in animal models. It has been studied in a model of diabetes induced by streptozotocin (STZ). The compound has shown antioxidant, anti-inflammatory, and antitumor activities in vivo. Further research is needed to fully characterize its in vivo pharmacological effects and potential therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for chrysoeriol typically involve studying its interaction with various molecular targets. The compound has been shown to inhibit PDGF-Rbeta phosphorylation. Binding studies may be conducted to assess its interaction with kinases and other signaling proteins. Additionally, assays may be performed to study its antioxidant activity, including free radical scavenging assays.
|
| Cell Assay |
In vitro cell-based assays for chrysoeriol typically involve treatment of cultured cells with the compound followed by assessment of various cellular responses. Anti-inflammatory assays measure the inhibition of nitric oxide production and cytokine secretion. Antitumor assays assess the inhibition of cell proliferation and induction of apoptosis. Antimicrobial assays evaluate the activity against bacteria and viruses.
|
| Animal Protocol |
In vivo animal studies for chrysoeriol typically involve administration to animal models to evaluate its pharmacological effects. The compound has been studied in a model of diabetes induced by streptozotocin. Typical protocols involve administering chrysoeriol to disease-relevant animal models, followed by assessment of disease progression, biomarker levels, and histopathological analysis.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Hypericin's known human metabolites include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxochromen-7-yl]oxooxetane-2-carboxylic acid. Chrysoeriol has a molecular formula of C16H12O6 and a molecular weight of 300.26. The CAS number is 491-71-4. The compound appears as a yellow powder. It has a melting point of >258°C (dec.). It is soluble in DMSO and methanol. It should be stored at 4°C and is hygroscopic. The compound is intended for research use only. |
| Toxicity/Toxicokinetics |
The toxicity profile of chrysoeriol is not extensively characterized, as it is a naturally occurring flavonoid. It is generally considered safe for use in research. The compound is intended for research use only and is not approved for therapeutic use in humans. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
4',5,7-Trihydroxy-3'-methoxyflavonoid is a 3'-O-methyl derivative of luteolin. It possesses antitumor, antioxidant, and metabolic activities. It is a trihydroxyflavonoid and a monomethoxyflavonoid. Its function is related to luteolin. It is the conjugate acid of 4',5-dihydroxy-3'-methoxyflavonoid-7-ol (1-). Hypericin has been reported in African perilla (Schouwia thebaica), perilla (Perilla frutescens), and other organisms with relevant data. See also: acai berry (part); acai berry pulp (part).
Chrysoeriol (CAS 491-71-4) is a naturally occurring monomethoxyflavone, specifically the 3'-O-methyl ether derivative of luteolin. It has antioxidant, anti-inflammatory, antitumor, antimicrobial, antiviral, and free radical scavenging activities. It inhibits AP-1 activation and PDGF-Rbeta phosphorylation. It has a molecular formula of C16H12O6 and a molecular weight of 300.26. |
| Molecular Formula |
C16H12O6
|
|---|---|
| Molecular Weight |
300.26
|
| Exact Mass |
300.063
|
| CAS # |
491-71-4
|
| PubChem CID |
5280666
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
574.3±50.0 °C at 760 mmHg
|
| Melting Point |
330 - 331 °C
|
| Flash Point |
219.4±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
1.81
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
|
| InChi Key |
SCZVLDHREVKTSH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-7,17-19H,1H3
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~333.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.33 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | |
| 5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
